GENESIS: AIMOVIG® Pregnancy Exposure Registry
Amgen
Summary
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
Eligibility
- Age range
- 18–99 years
- Sex
- Female
- Healthy volunteers
- Yes
Inclusion Criteria: * Age 18 years or older (at time of signing the informed consent) * Currently pregnant * The outcome of the pregnancy must not be known * Confirmed clinical diagnosis of migraine Exclusion Criteria: * Women currently participating in another investigational device or investigational drug study, currently taking an investigational medicinal product, or having taken an investigational product within 3 months prior to last menstrual period (LMP) or during pregnancy. Other investigational procedures while participating in this study are excluded. * Women exposed to any medic…
Interventions
- Drugerenumab-aooe
Dose and treatment duration will be advised by the HCP
Location
- IQVIA Virtual SiteDurham, North Carolina